JP2023017050A5 - - Google Patents

Download PDF

Info

Publication number
JP2023017050A5
JP2023017050A5 JP2022197027A JP2022197027A JP2023017050A5 JP 2023017050 A5 JP2023017050 A5 JP 2023017050A5 JP 2022197027 A JP2022197027 A JP 2022197027A JP 2022197027 A JP2022197027 A JP 2022197027A JP 2023017050 A5 JP2023017050 A5 JP 2023017050A5
Authority
JP
Japan
Prior art keywords
inhibitor according
administered
decrease
acceptable salt
period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022197027A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023017050A (ja
JP7424676B2 (ja
Filing date
Publication date
Priority claimed from JP2021038816A external-priority patent/JP7236753B2/ja
Application filed filed Critical
Publication of JP2023017050A publication Critical patent/JP2023017050A/ja
Publication of JP2023017050A5 publication Critical patent/JP2023017050A5/ja
Priority to JP2024002286A priority Critical patent/JP2024026709A/ja
Application granted granted Critical
Publication of JP7424676B2 publication Critical patent/JP7424676B2/ja
Priority to JP2024195194A priority patent/JP2025013575A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022197027A 2017-03-06 2022-12-09 マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤 Active JP7424676B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024002286A JP2024026709A (ja) 2017-03-06 2024-01-11 マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤
JP2024195194A JP2025013575A (ja) 2017-03-06 2024-11-07 マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017041349 2017-03-06
JP2017041349 2017-03-06
JP2021038816A JP7236753B2 (ja) 2017-03-06 2021-03-11 マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021038816A Division JP7236753B2 (ja) 2017-03-06 2021-03-11 マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024002286A Division JP2024026709A (ja) 2017-03-06 2024-01-11 マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤

Publications (3)

Publication Number Publication Date
JP2023017050A JP2023017050A (ja) 2023-02-02
JP2023017050A5 true JP2023017050A5 (https=) 2023-09-26
JP7424676B2 JP7424676B2 (ja) 2024-01-30

Family

ID=63448602

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2019504597A Active JP6637217B2 (ja) 2017-03-06 2018-03-06 近視予防又は抑制剤、マウス近視誘導モデルの作製方法、及び、近視予防又は抑制医薬スクリーニング方法
JP2019202287A Active JP6856275B2 (ja) 2017-03-06 2019-11-07 近視予防、治療又は抑制用点眼剤
JP2021038816A Active JP7236753B2 (ja) 2017-03-06 2021-03-11 マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤
JP2022197027A Active JP7424676B2 (ja) 2017-03-06 2022-12-09 マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤
JP2024002286A Withdrawn JP2024026709A (ja) 2017-03-06 2024-01-11 マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤
JP2024195194A Pending JP2025013575A (ja) 2017-03-06 2024-11-07 マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2019504597A Active JP6637217B2 (ja) 2017-03-06 2018-03-06 近視予防又は抑制剤、マウス近視誘導モデルの作製方法、及び、近視予防又は抑制医薬スクリーニング方法
JP2019202287A Active JP6856275B2 (ja) 2017-03-06 2019-11-07 近視予防、治療又は抑制用点眼剤
JP2021038816A Active JP7236753B2 (ja) 2017-03-06 2021-03-11 マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024002286A Withdrawn JP2024026709A (ja) 2017-03-06 2024-01-11 マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤
JP2024195194A Pending JP2025013575A (ja) 2017-03-06 2024-11-07 マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤

Country Status (13)

Country Link
US (2) US12478597B2 (https=)
EP (1) EP3593817B1 (https=)
JP (6) JP6637217B2 (https=)
KR (1) KR102680012B1 (https=)
CN (3) CN115645536A (https=)
DK (1) DK3593817T3 (https=)
ES (1) ES2997337T3 (https=)
FI (1) FI3593817T3 (https=)
HR (1) HRP20241734T1 (https=)
HU (1) HUE069999T2 (https=)
PL (1) PL3593817T3 (https=)
PT (1) PT3593817T (https=)
WO (1) WO2018164113A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021007161A (es) * 2018-12-18 2021-10-13 Santen Pharmaceutical Co Ltd Agente que contiene acido ursodesoxicolico para tratar o prevenir la presbicia.
KR102902220B1 (ko) * 2018-12-18 2025-12-18 산텐 세이야꾸 가부시키가이샤 4-페닐부티르산을 함유하는 노시의 치료 또는 예방제
JP7608707B2 (ja) * 2019-02-25 2025-01-07 株式会社坪田ラボ 近視進行抑制剤、機能性食品及び眼科用組成物
EP3934754A4 (en) * 2019-03-08 2022-11-23 The Regents Of The University Of California COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY INSUFFICIENCY
CA3182437A1 (en) * 2020-06-11 2021-12-16 Andrei V. Tkatchenko Methods and compositions for preventing and treating myopia with berberine, a berberidaceaen alkaloid, and derivatives thereof
US20240041806A1 (en) * 2020-12-11 2024-02-08 Tsubota Laboratory, Inc. Eyedrops for Inhibiting Myopia Progression in Children and Screening Method for Inhibitor of Myopia Progression in Children
EP4257148A4 (en) * 2020-12-11 2024-11-06 Tsubota Laboratory, Inc. EYE DROPS FOR TREATMENT OF SCLERAL THINNING AND SCREENING METHOD FOR SCLERAL THINNING THERAPEUTIC AGENT
CN112970666B (zh) * 2021-02-04 2023-02-03 复旦大学附属眼耳鼻喉科医院 一种简便式动物近视诱导装置及制作方法
JP2024069730A (ja) * 2021-03-16 2024-05-22 慶應義塾 網膜変性抑制用組成物
JPWO2023145578A1 (https=) * 2022-01-25 2023-08-03
WO2023182480A1 (ja) 2022-03-25 2023-09-28 株式会社坪田ラボ 水性組成物
AU2023258808A1 (en) * 2022-04-26 2024-11-07 Tsubota Laboratory, Inc. Method and composition for preventing or treating myopia
CN119998296A (zh) * 2022-08-31 2025-05-13 国立大学法人京都大学 化合物、内质网应激抑制剂、药物、眼科用药、滴眼剂、组合物、化合物的制备方法
CN115777618B (zh) * 2022-11-14 2025-07-08 首都医科大学附属北京同仁医院 一种病理性近视动物模型的构建方法及用途
CN116267712B (zh) * 2023-02-23 2024-08-06 温州医科大学 一种近视眼动物模型的构建方法及其应用
JPWO2024203727A1 (https=) * 2023-03-24 2024-10-03
CN116918764B (zh) * 2023-08-28 2025-11-28 河南省儿童医院郑州儿童医院 一种豚鼠近视模型的构建方法
WO2025063144A1 (ja) 2023-09-22 2025-03-27 株式会社坪田ラボ 水性組成物
JP7781461B2 (ja) * 2023-10-25 2025-12-08 株式会社坪田ラボ 近視を予防または治療するための方法および組成物
WO2025089394A1 (ja) * 2023-10-25 2025-05-01 株式会社坪田ラボ 近視を予防または治療するための方法および組成物
CN117797133A (zh) * 2023-12-29 2024-04-02 上海交通大学医学院附属仁济医院 内质网应激抑制剂isrib在制备胎儿宫内生长受限药物中的应用
WO2025182819A1 (ja) * 2024-02-29 2025-09-04 慶應義塾 動物モデルの作製方法
CN118892097A (zh) * 2024-07-18 2024-11-05 海南省眼科医院(中山大学中山眼科中心海南眼科医院) 一种基于自然光照明的近视延缓方法
CN120392754B (zh) * 2025-07-02 2025-09-09 深圳市中佳生物医疗科技有限公司 化合物在制备增强造血干细胞代谢活性、治疗异染性脑白质营养不良的产品中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3066561B2 (ja) 1993-10-07 2000-07-17 武田薬品工業株式会社 近視予防・治療剤
JPH09315954A (ja) 1996-05-30 1997-12-09 Kita:Kk 眼科手術後の眼組織混濁防止剤。
CA2400803A1 (en) 2000-01-18 2001-07-26 Richard A. Stone Ocular growth and nicotinic antagonists
CN1191074C (zh) * 2002-09-18 2005-03-02 王力 熊胆粉滴眼液及其制备方法
MXPA03011987A (es) 2003-12-19 2005-06-23 Osio Sancho Alberto Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
CN101056656A (zh) 2004-09-15 2007-10-17 哈佛大学校长及研究员协会 在治疗肥胖症和糖尿病中降低er应力
US20060073213A1 (en) * 2004-09-15 2006-04-06 Hotamisligil Gokhan S Reducing ER stress in the treatment of obesity and diabetes
US20110130388A1 (en) * 2008-07-24 2011-06-02 Yasushi Ikuno Prophylactic or therapeutic agent for axial myopia
UY33288A (es) 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
CA2794153C (en) * 2010-03-25 2018-01-02 Glaxosmithkline Llc Substituted indoline derivatives as perk inhibitors
US8962686B2 (en) 2010-04-28 2015-02-24 The Chinese University Of Hong Kong Method and medication for prevention and treatment of ocular hypertension and glaucoma
PH12013501490A1 (en) 2011-01-14 2019-03-13 Univ Washington Through Its Center For Commercialization Methods for diagnosing and treating eye-length related disorders
WO2013025840A1 (en) * 2011-08-15 2013-02-21 Massachusetts Eye And Ear Infirmary Methods for preserving photoreceptor cell viability following retinal detachment
GB201217296D0 (en) * 2012-09-27 2012-11-14 Alta Innovations Ltd Method of treatment and/or prevention
WO2015056180A1 (en) * 2013-10-15 2015-04-23 Glaxosmithkline Intellectual Property (No.2) Limited Indoline derivatives as inhibitors of perk
CA2927898C (en) 2013-10-31 2021-11-16 Kyoto Prefectural Public University Corporation Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
WO2016171282A1 (ja) * 2015-04-24 2016-10-27 学校法人慶應義塾 近視予防剤及び近視進行抑制剤

Similar Documents

Publication Publication Date Title
JP2023017050A5 (https=)
JP2020023574A5 (ja) 近視予防、治療又は抑制用点眼剤、及び、小胞体ストレス抑制用点眼剤
JP7424676B2 (ja) マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤
AU2014363599B2 (en) Orally disintegrating solid dosage unit containing an estetrol component
JP6666487B2 (ja) ドライアイ治療用点眼剤
Rodrigues et al. Nonsteroidal Anti-Inflammatory Drugs in the
CN101888839A (zh) 治疗眼睛病症的脂氧化物类化合物
JP2014515383A5 (https=)
ES2335181A1 (es) Combinacion de sustancias activas.
JP2021046394A5 (https=)
JP2021006548A5 (https=)
JP2019530729A5 (https=)
JP2017529377A5 (https=)
RU2018102746A (ru) Офтальмологическая фармацевтическая композиция
CA2964684A1 (en) Composition for the treatment of conditions involving muscular pain
AU2012265231B2 (en) Nasal pharmaceutical formulation
US9867789B2 (en) Non-steroidal anti-inflammatory drugs for cough
JP2013519695A5 (https=)
CN104994839A (zh) 局部眼用镇痛剂
JP2019511996A5 (https=)
WO2013158961A1 (en) Combination of a non-steroidal anti-inflammatory drug with an anti-histaminic drug intended for ophthalmic use
AU725697B2 (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia
JPWO2023165334A5 (https=)
WO2011067663A1 (en) Pharmaceutical preparations comprising phloroglucinol and/or derivatives thereof and some non-steroidal anti-inflammatory drugs and their use in the treatment and/or prevention of pain syndromes of the feminine genital system
IL320636A (en) Benzaldehyde compounds with destabilizing effects on polymers for the treatment of sickle cell disease